evogliptin + pioglitazone

Evogliptin + pioglitazone is a fixed-dose combination of two oral antidiabetic agents used for the management of type 2 diabetes mellitus. Evogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by increasing incretin levels, thereby enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner. Pioglitazone is a thiazolidinedione that acts as an agonist at peroxisome proliferator-activated receptor gamma (PPARγ), improving insulin sensitivity in adipose tissue, skeletal muscle, and liver. The combination aims to provide complementary mechanisms for glycemic control without significant pharmacokinetic interactions between the two drugs[1][3][4]. This combination has been shown to have additive glucose-lowering effects compared to monotherapy with either agent[1][4].